Abstract
During the course of adulthood and ageing, white matter (WM) structure and organisation are characterised by slow degradation processes such as demyelination and shrinkage. An acceleration of such ageing process has been linked to the development of a range of diseases. Thus, an accurate description of healthy brain maturation, in particular, in terms of WM features, provides a cornerstone in the understanding of ageing. We use longitudinal diffusion magnetic resonance imaging to provide an overview of WM changes at different spatial and temporal scales in the UK Biobank (UKB) (N=2,678; agescan1=62.38±7.23 years; agescan2=64.81±7.1 years). To examine the genetic overlap between WM structure and common clinical conditions, we tested the associations between WM structure and polygenic risk scores (PGRS) for the most common neurodegenerative disorder, Alzheimer’s disease, and common psychiatric disorders (uniand bipolar depression, anxiety, obsessive-compulsive, autism, schizophrenia, attention-deficit-hyperactivity) in longitudinal (N=2,329) and crosssectional UKB validation data (N=31,056). Global and regional single and multi-compartment fractional anisotropy, intra-axonal water fraction, and kurtosis metrics decreased , whereas diffusivity metrics, and free water increased with age
, with the annual rate of WM change (ARoC) accelerating at higher ages for both global
and regional WM metrics
. Voxel-level trends indicated decreasing anisotropy, and variable spatial patterns for other diffusion metrics, suggesting differential changes in frontal compared to other brain regions. Although effect sizes were small
, ARoC in middle cerebral peduncle WM had the strongest association with PGRS, especially for Alzheimer’s:
. PGRS were more strongly related to ARoC than cross-sectional measures (dscan1=0.03, dscan2=0.03, dvalidation=0.03). Our findings indicate spatially distributed WM changes across the brain, as well as distributed associations of PGRS with WM. Importantly, brain longitudinal changes reflected the genetic risk for disorder development better than the utilised cross-sectional measures, with regional differences giving more specific insights into gene-brain change associations than global averages.
Competing Interest Statement
OAA has received a speaker's honorarium from Lundbeck and is a consultant to Coretechs.ai.
Funding Statement
This research was funded by the Research Council of Norway (#223273, #300767); the South-Eastern Norway Regional Health Authority (#2022080, #2019101); and the European Union's Horizon2020 Research and Innovation Programme (#847776, #802998).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study has been conducted using UKB data under Application 27412.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available from the UK Biobank (https://www.ukbiobank.ac.uk/).